Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab
Published Online: 2014-01-28
Journal: Investigational New Drugs•Publisher: Springer Science and Business Media LLC
Authors: Hee Cheol Kim•Ho Yeong Lim•Hye Jin Kang•In-Gu Do•Insuk Sohn•Jeeyun Lee•Joon Oh Park•Jung Yong Hong•Kyoung-Mee Kim•Kyu-pyo Kim•Se Hoon Park•Se Won Han•Seong Hyeon Yun•Suk Hyung Kim•Tae Won Kim•Tae You Kim•Won Ki Kang•Woo Yong Lee•Yong Beom Cho•Yong Sang Hong•Young Suk Park
